Carbamazepine, a minuscule molecule drug, exerts its therapeutic effect through the blocking of sodium channels in the human body.

Ultomiris receives US green light to treat adult patients with spectrum disorder related to neuromyelitis optica (NMOSD).

This article introduces the new drugs related to GPCR that were approved by the FDA in 2023.

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH).

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101.

Nitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024.

Recently, AstraZeneca reported in detail the discovery process of the RXFP1 agonist AZD5462, currently in Phase II clinical trials, in two consecutive articles published in the top-tier journal JMC (Journal of Medicinal Chemistry).

Chugai Pharmaceutical revealed Phase III LUMINESCE trial results for their drug Enspryng (satralizumab).

Atomoxetine, a diminutive molecule drug concocted by Eli Lilly, procured its inaugural medical approval in 2002.

FDA Approves NMD Pharma's IND Application for Phase 2b Trial of NMD670 in US Myasthenia Gravis Population.

On March 18th, Bristol Myers Squibb (BMS) finalized its acquisition of Karuna Therapeutics, enhancing its neuroscience investments. Karuna has stopped NASDAQ trading and is now fully owned by BMS.